Read by QxMD icon Read


Maria Chiara Chindamo, Jerome Boursier, Ronir Raggio Luiz, Isabelle Fouchard-Hubert, Vera Lúcia Nunes Pannain, João Marcello de Araújo Neto, Henrique Sérgio Moraes Coelho, Renata de Mello Perez, Paul Calès, Cristiane Alves Villela-Nogueira
AIM: To evaluate the performance of FibroMeter(Virus3G) combined to the first generation tests aspartate aminotransferase-to-platelet ratio index (APRI) or Forns index to assess significant fibrosis in chronic hepatitis C (CHC). METHODS: First generation tests APRI or Forns were initially applied in a derivation population from Rio de Janeiro in Brazil considering cut-offs previously reported in the literature to evaluate significant fibrosis. FibroMeter(Virus3G) was sequentially applied to unclassified cases from APRI or Forns...
February 28, 2017: World Journal of Hepatology
P Calès, J Boursier, J Lebigot, V de Ledinghen, C Aubé, I Hubert, F Oberti
BACKGROUND: In chronic hepatitis C, the European Association for the Study of the Liver - Asociacion Latinoamericana para el Estudio del Higado recommends performing transient elastography and a blood test to diagnose significant fibrosis; test concordance confirms diagnosis. AIM: To validate this rule and improve it by combining a blood test, FibroMeter (virus second generation, Echosens, Paris, France) and transient elastography (constitutive tests) into a single combined test, as suggested by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America...
February 6, 2017: Alimentary Pharmacology & Therapeutics
Jérôme Boursier, Victor de Ledinghen, Vincent Leroy, Rodolphe Anty, Sven Francque, Dominique Salmon, Adrien Lannes, Sandrine Bertrais, Frederic Oberti, Isabelle Fouchard-Hubert, Paul Calès
BACKGROUND & AIMS: Chronic liver diseases (CLD) are common, and are therefore mainly managed by non-hepatologists. These physicians lack access to the best non-invasive tests of liver fibrosis, and consequently cannot accurately determine the disease severity. Referral to a hepatologist is then needed. We aimed to implement an algorithm, comprising a new first-line test usable by all physicians, for the detection of advanced liver fibrosis in all CLD patients. METHODS: Diagnostic study: 3754 CLD patients with liver biopsy were 2:1 randomized into derivation and validation sets...
January 12, 2017: Journal of Hepatology
Thomson Chi-Wang Loong, Jeremy Lok Wei, Jonathan Chung-Fai Leung, Grace Lai-Hung Wong, Sally She-Ting Shu, Angel Mei-Ling Chim, Anthony Wing-Hung Chan, Paul Cheung-Lung Choi, Yee-Kit Tse, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong
BACKGROUND AND AIM: The FM VCTE is a new formula combining the serum test FibroMeter (FM) and liver stiffness measurement (LSM) by vibration controlled transient elastography (VCTE). We tested the accuracy and utility of FM VCTE for fibrosis staging in patients with non-alcoholic fatty liver disease (NAFLD). METHODS: 215 NAFLD patients with LSM, FM NAFLD, FM VCTE and other serum tests (aspartate aminotransferase [AST]-to-platelet ratio index, FIB-4 index, BARD score, NAFLD fibrosis score and AST-to-alanine aminotransferase ratio) performed 1 day before liver biopsy were evaluated...
December 9, 2016: Journal of Gastroenterology and Hepatology
Sandrine Bertrais, Jérôme Boursier, Alexandra Ducancelle, Frédéric Oberti, Isabelle Fouchard-Hubert, Valérie Moal, Paul Calès
BACKGROUND AND AIM: There is currently no recommended time interval between non-invasive fibrosis measurements for monitoring chronic liver diseases. We determined how long a single liver fibrosis evaluation may accurately predict mortality, and assessed whether combining tests improves prognostic performance. METHODS: We included 1559 patients with chronic liver disease and available baseline liver stiffness measurement (LSM) by Fibroscan, APRI, FIB-4, Hepascore, and FibroMeter(V2G) ...
November 29, 2016: Journal of Gastroenterology and Hepatology
Sudeep Tanwar, Paul M Trembling, Brian J Hogan, Julie Parkes, Scott Harris, Paul Grant, Eleni Nastouli, Mathias Ocker, Klaus Wehr, Christoph Herold, Daniel Neureiter, Detlef Schuppan, William M Rosenberg
BACKGROUND: Advancing fibrosis is regarded as the most important factor when stratifying patients with chronic hepatitis C for retreatment. GOALS: (1) To compare the performance of 10 biomarkers of fibrosis, including patented tests, among patients with chronic hepatitis C and treatment failure; and (2) to assess the impact on biomarker performance of using 2 different assays of hyaluronic acid (HA). STUDY: For 80 patients, liver histology (Metavir) was compared with biomarker scores using sera obtained within 6 months of liver biopsy (indirect biomarkers: AST:ALT ratio, APRI, Forns index, FIB-4, Fibrometer V3G; direct biomarkers: ELF, Fibrospect II, Hyaluronic acid-HA, Fibrometer V2G, Hepascore)...
March 2017: Journal of Clinical Gastroenterology
Marco Merli, Laura Galli, Antonella Castagna, Stefania Salpietro, Nicola Gianotti, Emanuela Messina, Andrea Poli, Giulia Morsica, Sabrina Bagaglio, Massimo Cernuschi, Alba Bigoloni, Caterina Uberti-Foppa, Adriano Lazzarin, Hamid Hasson
We determined the diagnostic accuracy and optimal cut off of three indirect fibrosis biomarkers (APRI, FIB-4, Forns) compared with liver stiffness (LS) for the detection of liver cirrhosis in HIV/HCV-coinfected patients. An observational retrospective study on HIV/HCV-coinfected patients with concomitant LS measurement and APRI, FIB-4 and Forns was performed. The presence of liver cirrhosis was defined as a LS ≥13 KPa. The diagnostic accuracy and optimal cut-off values, compared with LS categorization (<13 vs ≥13 KPa), were determined by receiver operating characteristics (ROC) curves...
2016: New Microbiologica
Wojciech Trzepizur, Jérôme Boursier, Yasmina Mansour, Marc Le Vaillant, Sylvaine Chollet, Thierry Pigeanne, Acya Bizieux-Thaminy, Marie-Pierre Humeau, Claire Alizon, François Goupil, Nicole Meslier, Pascaline Priou, Paul Calès, Frédéric Gagnadoux
Obstructive sleep apnea (OSA) may contribute to the development of nonalcoholic fatty liver disease. We performed a multisite cross-sectional study to evaluate the association between the severity of OSA and blood markers of liver steatosis (using the hepatic steatosis index), cytolysis (based on alanine aminotransferase activity), and significant liver fibrosis (based on the FibroMeter [Echosens] nonalcoholic fatty liver disease score) in 1285 patients with suspected OSA in France. After adjusting for confounders including central obesity, the risk of liver steatosis increased with the severity of OSA (P for trend < ...
November 2016: Clinical Gastroenterology and Hepatology
Jérôme Boursier, Julien Vergniol, Anne Guillet, Jean-Baptiste Hiriart, Adrien Lannes, Brigitte Le Bail, Sophie Michalak, Faiza Chermak, Sandrine Bertrais, Juliette Foucher, Frédéric Oberti, Maude Charbonnier, Isabelle Fouchard-Hubert, Marie-Christine Rousselet, Paul Calès, Victor de Lédinghen
BACKGROUND & AIMS: NAFLD is highly prevalent but only a small subset of patients develop advanced liver fibrosis with impaired liver-related prognosis. We aimed to compare blood fibrosis tests and liver stiffness measurement (LSM) by FibroScan for the diagnosis of liver fibrosis and the evaluation of prognosis in NAFLD. METHODS: Diagnostic accuracy was evaluated in a cross-sectional study including 452 NAFLD patients with liver biopsy (NASH-CRN fibrosis stage), LSM, and eight blood fibrosis tests (BARD, NAFLD fibrosis score, FibroMeter(NAFLD), aspartate aminotransferase to platelet ratio index (APRI), FIB4, FibroTest, Hepascore, FibroMeter(V2G))...
September 2016: Journal of Hepatology
Mohammad S Siddiqui, Kavish R Patidar, Sherry Boyett, Velimir A Luketic, Puneet Puri, Arun J Sanyal
BACKGROUND & AIMS: In non-alcoholic fatty liver disease, presence of fibrosis is predictive of long-term liver-related complications. Currently, there are no reliable and non-invasive means of quantifying fibrosis in those with non-alcoholic fatty liver disease. Therefore, we aimed to evaluate the performance of a panel of non-invasive models in predicting fibrosis in non-alcoholic fatty liver disease. METHODS: The accuracy of FibroMeter non-alcoholic fatty liver disease, fibrosis 4 and four other non-invasive models in predicting fibrosis in those with biopsy proven non-alcoholic fatty liver disease was compared...
April 2016: Liver International: Official Journal of the International Association for the Study of the Liver
Marta Kucharska, Marcin Inglot, Małgorzata Kuliszkiewicz-Janus, Monika Pazgan-Simon, Brygida Knysz
Haemophilia is an entity, wherein the HCV infection rate is greater than in the general population and ranges between 70-90%. The majority of HCV infections were acquired by hemophiliacs in the 1980s, by the use of infected cryoprecipitate or fresh frozen plasma preparations. It is therefore highly likely that many of them, more than twenty years after the infection, have developed advanced liver disease. Until recently, in order to assess its severity, it was necessary to perform a liver biopsy. Currently, we observe rapid developments of non-invasive methods that are particularly useful in patients with bleeding disorders...
July 2015: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
Sim Yee Ong, Lara Dolling, Jeannette L Dixon, Amanda J Nicoll, Lyle C Gurrin, Michelle Wolthuizen, Erica M Wood, Greg J Anderson, Grant A Ramm, Katrina J Allen, John K Olynyk, Darrell Crawford, Jennifer Kava, Louise E Ramm, Paul Gow, Simon Durrant, Lawrie W Powell, Martin B Delatycki
INTRODUCTION: HFE p.C282Y homozygosity is the most common cause of hereditary haemochromatosis. There is currently insufficient evidence to assess whether non-specific symptoms or hepatic injury in homozygotes with moderately elevated iron defined as a serum ferritin (SF) of 300-1000 µg/L are related to iron overload. As such the evidence for intervention in this group is lacking. We present here methods for a study that aims to evaluate whether non-specific symptoms and hepatic fibrosis markers improve with short-term normalisation of SF in p...
August 12, 2015: BMJ Open
Emmanuel A Tsochatzis, Laurent Castera
PURPOSE OF REVIEW: It is estimated that up to 10% of patients with HIV have chronic hepatitis C (HCV)-HIV coinfection in the Western world. Assessment of liver disease is essential in such patients in order to diagnose cirrhosis at an early stage, prioritize for anti-HCV treatment but also assess fibrosis regression after sustained viral response (SVR). In this review, we present a critical appraisal of liver disease assessment in patients with HIV-HCV co-infection. RECENT FINDINGS: Liver biopsy has largely been replaced by noninvasive fibrosis assessment in most coinfected patients, although it is still of value if there are concerns of additional diagnoses...
September 2015: Current Opinion in HIV and AIDS
Elif Dincses, Yusuf Yilmaz
BACKGROUND: Liver fibrosis is an important prognostic determinant in patients with nonalcoholic fatty liver disease (NAFLD). The FibroMeter VCTE is a diagnostic tool comprising both biochemical markers and transient elastography (TE) originally developed for the diagnosis of fibrosis in patients with chronic viral hepatitis. In this pilot study, we investigated the diagnostic performance of the FibroMeter VCTE tool for determining fibrosis in patients with biopsy-proven NAFLD. Its diagnostic accuracy was also compared with those of the NAFLD fibrosis score (NFSA) and TE alone...
October 2015: European Journal of Gastroenterology & Hepatology
Anil Arora, Praveen Sharma
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in developed as well as in developing countries. Its prevalence continues to rise currently affecting approximately 20-30% of adults and 10% of children in the United States. Non-alcoholic fatty liver disease represents a wide spectrum of conditions ranging from fatty liver, which in general follows a benign non-progressive clinical course, to non-alcoholic steatohepatitis (NASH), a more serious form of NAFLD that may progress to cirrhosis and end-stage liver disease...
June 2012: Journal of Clinical and Experimental Hepatology
Cemal F Subasi, Umut E Aykut, Yusuf Yilmaz
BACKGROUND: The presence of advanced liver fibrosis portends a poor prognosis in nonalcoholic fatty liver disease (NAFLD). We aimed to compare the diagnostic performance of five noninvasive scores [aspartate aminotransferase/platelet ratio (APRI), BARD, FIB-4, NAFLD fibrosis score (NFSA), and FibroMeter] for the assessment of advanced stages of fibrosis (F ≥ 3) in patients with biopsy-proven NAFLD. METHODS: APRI, BARD, FIB-4, NFSA, and FibroMeter scores were determined in 142 patients with NAFLD...
February 2015: European Journal of Gastroenterology & Hepatology
Umut Emre Aykut, Umit Akyuz, Atakan Yesil, Fatih Eren, Fatma Gerin, Rabia Ergelen, Cigdem Ataizi Celikel, Yusuf Yilmaz
BACKGROUND: Noninvasive markers that purport to distinguish patients with non-alcoholic fatty liver disease (NAFLD) with fibrosis from those without must be evaluated rigorously for their classification accuracy. Herein, we seek to compare the diagnostic performances of three different noninvasive methods (FibroMeter™ NAFLD score, NAFLD Fibrosis score (NFSA), and Transient Elastrography [TE]) for the detection of liver fibrosis in NAFLD patients. METHODS: A total of 88 patients with biopsy-proven NAFLD were included...
November 2014: Scandinavian Journal of Gastroenterology
J Boursier, C Brochard, S Bertrais, S Michalak, Y Gallois, I Fouchard-Hubert, F Oberti, M-C Rousselet, P Calès
BACKGROUND: Recent longitudinal studies have emphasised the prognostic value of noninvasive tests of liver fibrosis and cross-sectional studies have shown their combination significantly improves diagnostic accuracy. AIM: To compare the prognostic accuracy of six blood fibrosis tests and liver biopsy, and evaluate if test combination improves the liver-prognosis assessment in chronic hepatitis C (CHC). METHODS: A total of 373 patients with compensated CHC, liver biopsy (Metavir F) and blood tests targeting fibrosis (APRI, FIB4, Fibrotest, Hepascore, FibroMeter) or cirrhosis (CirrhoMeter) were included...
July 2014: Alimentary Pharmacology & Therapeutics
Vincent Leroy, Nathalie Sturm, Patrice Faure, Candice Trocme, Alice Marlu, Marie-Noëlle Hilleret, Françoise Morel, Jean-Pierre Zarski
BACKGROUND & AIMS: Fibrosis blood tests have been validated in chronic hepatitis C. Their diagnostic accuracy is less documented in hepatitis B. The aim of this study was to describe the diagnostic performance of FibroTest®, FibroMeter®, and HepaScore® for liver fibrosis in hepatitis B compared to hepatitis C. METHODS: 510 patients mono-infected with hepatitis B or C and matched on fibrosis stage were included. Blood tests were performed the day of the liver biopsy...
July 2014: Journal of Hepatology
Paul Calès, Jérôme Boursier, Alexandra Ducancelle, Frédéric Oberti, Isabelle Hubert, Gilles Hunault, Victor de Lédinghen, Jean-Pierre Zarski, Dominique Salmon, Françoise Lunel
AIMS: Our main objective was to improve non-invasive fibrosis staging accuracy by resolving the limits of previous methods via new test combinations. Our secondary objectives were to improve staging precision, by developing a detailed fibrosis classification, and reliability (personalized accuracy) determination. METHODS: All patients (729) included in the derivation population had chronic hepatitis C, liver biopsy, 6 blood tests and Fibroscan. Validation populations included 1584 patients...
July 2014: Liver International: Official Journal of the International Association for the Study of the Liver
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"